Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Investment Securities (2021 - 2025)

Historic Gains from Investment Securities for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $815000.0.

  • Janux Therapeutics' Gains from Investment Securities fell 9137.29% to $815000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $32.7 million, marking a year-over-year increase of 28255.27%. This contributed to the annual value of $8.9 million for FY2024, which is 1106.34% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Gains from Investment Securities is $815000.0, which was down 9137.29% from $10.2 million recorded in Q2 2025.
  • Janux Therapeutics' Gains from Investment Securities' 5-year high stood at $23.5 million during Q4 2024, with a 5-year trough of -$1.1 million in Q2 2024.
  • For the 5-year period, Janux Therapeutics' Gains from Investment Securities averaged around $5.5 million, with its median value being $5.4 million (2021).
  • The largest annual percentage gain for Janux Therapeutics' Gains from Investment Securities in the last 5 years was 831478.26% (2024), contrasted with its biggest fall of 24018.69% (2024).
  • Over the past 5 years, Janux Therapeutics' Gains from Investment Securities (Quarter) stood at $5.5 million in 2021, then crashed by 93.8% to $344000.0 in 2022, then fell by 12.79% to $300000.0 in 2023, then surged by 7733.33% to $23.5 million in 2024, then tumbled by 96.53% to $815000.0 in 2025.
  • Its Gains from Investment Securities stands at $815000.0 for Q3 2025, versus $10.2 million for Q2 2025 and $10.0 million for Q1 2025.